In a typical adult patient with toxic epidermal necrolysis, what is the evidence comparing intravenous corticosteroids, cyclosporine, and intravenous immune globulin for management?

Management of TEN: IV Steroids vs Cyclosporine vs IVIG

Based on the most recent high-quality evidence, cyclosporine appears to be the most effective single agent for TEN, showing superior mortality reduction compared to IVIG and faster re-epithelialization compared to supportive care alone. However, the 2016 UK guidelines emphasize that no treatment has conclusive superiority over high-quality supportive care 1.

Evidence Quality and Hierarchy

The evidence base for TEN treatment remains problematic—there are no randomized controlled trials comparing these three agents head-to-head, and most data comes from retrospective case series with significant methodological limitations 1. The 2016 UK guidelines explicitly state they "found interpretation of the reviewed studies challenging, given major ascertainment bias in reported cohorts, low numbers of patients, variation in the timing and nature of intervention, case mix and setting" 1.

Comparative Efficacy by Agent

Cyclosporine (Most Promising)

Cyclosporine at 3 mg/kg/day for 10 days shows the strongest mortality benefit:

• The Valeyrie-Allanore study demonstrated 0 deaths in 29 patients despite a SCORTEN-predicted mortality of 2.75/29 1
• A 2022 study showed cyclosporine reduced length of stay (13.0 vs 19.0 days, p=0.019) and systemic infection rates (36.0% vs 71.4%, p=0.017) compared to non-cyclosporine treatment 2
• A 2026 meta-analysis found cyclosporine superior to IVIG for mortality (RR 0.18,95% CI 0.05-0.58) 3
• Accelerates re-epithelialization compared to other treatments 2

Dosing: 3 mg/kg/day for 7-10 days, then taper over another 7 days 1

IVIG (Equivocal Evidence)

IVIG shows highly inconsistent results with no clear mortality benefit:

• Multiple studies show conflicting outcomes—some report 0% mortality, others up to 42% 1
• The 2013 Lee et al. study of 64 patients showed no mortality benefit compared to SCORTEN-predicted outcomes 1
• High-dose (>3 g/kg) vs low-dose (<3 g/kg) showed no mortality difference 1
• Brown et al. showed worse outcomes with IVIG: 42% mortality vs 29% in controls 1
• Firoz et al. demonstrated no improved survival vs supportive care alone 1

Critical caveat: The UK guidelines note "strong advocates for use and avoidance of IVIG" exist even among experienced clinicians, reflecting the controversy 1.

Corticosteroids (Mixed Evidence)

High-dose pulse corticosteroids show some promise but inconsistent results:

• Kardaun study: IV dexamethasone 100 mg or 1.5 mg/kg for 3 days showed decreased mortality compared to SCORTEN 1
• Hirahara et al.: IV methylprednisolone 1000 mg for 3 consecutive days resulted in 0 deaths despite SCORTEN-predicted mortality of 1.6 1
• EuroSCAR data showed lower mortality in German patients (but not French) treated with corticosteroids 1
• Major concern: Opponents argue systemic corticosteroids increase sepsis risk 1

Combination Therapy (Emerging Evidence)

Recent studies suggest combination approaches may be superior:

• Corticosteroids + IVIG reduced serious complications (sepsis RR 0.77,95% CI 0.31-0.77) compared to corticosteroids alone 3
• Adalimumab + corticosteroids reduced hospitalization (22 vs 25 days, p=0.032) and re-epithelialization time (17 vs 19 days, p=0.019) compared to traditional therapy 4
• A 2025 review supports combination supportive care with topical silver nitrate 0.5% plus single-dose etanercept 5

Practical Algorithm

Step 1: Immediate Actions

• Discontinue all suspected culprit drugs immediately
• Transfer to burn center or ICU with TEN experience if >10% BSA involvement 1
• Institute high-quality supportive care (this is non-negotiable and the foundation) 1

Step 2: Pharmacologic Intervention Decision

First-line recommendation: Cyclosporine 3 mg/kg/day

• Start within first 48-72 hours for maximum benefit
• Continue for 10 days, then taper over 7 days
• Monitor renal function (cyclosporine can cause nephrotoxicity) 6

Alternative if cyclosporine contraindicated:

• High-dose pulse IV methylprednisolone 1000 mg daily × 3 days, then taper
• OR IV dexamethasone 100 mg or 1.5 mg/kg daily × 3 days

Consider adding:

• Single dose subcutaneous etanercept 50 mg (emerging evidence) 1, 5
• Topical silver nitrate 0.5% to denuded areas 5

Avoid IVIG as monotherapy given inconsistent evidence and superior alternatives 3

Critical Pitfalls

1. Do not delay treatment waiting for definitive diagnosis—early intervention (within 48-72 hours) is crucial
2. Do not use IVIG alone as first-line given the 2026 meta-analysis showing cyclosporine superiority 3
3. Monitor for sepsis aggressively—this is the leading cause of death, not the skin disease itself 1
4. Avoid prophylactic antibiotics—increases Candida colonization; only use for documented infection 1
5. Do not assume all treatments are equal—the evidence hierarchy clearly favors cyclosporine over IVIG 3

Monitoring Parameters

• Neutrophil-to-lymphocyte ratio (NLR): High baseline NLR predicts severe complications; decreasing NLR after treatment indicates beneficial response (opposite for immune checkpoint inhibitor-related TEN) 7
• SCORTEN remains the only validated mortality predictor (each point increases risk ratio 1.96) 2
• Daily assessment of re-epithelialization and infection signs

Guideline Recommendation Context

The UK guidelines make no specific recommendation for or against any intervention (Strength D, Level 4 evidence), stating "there is no conclusive evidence to demonstrate the benefit of any one intervention over conservative management" and that "high-quality, multidisciplinary supportive care is the priority" 1. However, this 2016 guideline predates the more recent evidence favoring cyclosporine 2, 3.